The Role and Application of Vesicles in Triple-negative Breast Cancer: Opportunities and Challenges

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2023 Dec 22

PMID 38130701

Authors

Ya-Nan Wei

Chun-Yan Yan

Meng-Lu Zhao

Xi-He Zhao

Affiliations

Soon will be listed here.

Abstract

Extracellular vesicles (EVs) carry DNA, RNA, protein, and other substances involved in intercellular crosstalk and can be used for the targeted delivery of drugs. Triple-negative breast cancer (TNBC) is rich in recurrent and metastatic disease and lacks therapeutic targets. Studies have proved the role of EVs in the different stages of the genesis and development of TNBC. Cancer cells actively secrete various biomolecules, which play a significant part establishing the tumor microenvironment via EVs. In this article, we describe the roles of EVs in the tumor immune microenvironment, metabolic microenvironment, and vascular remodeling, and summarize the application of EVs for objective delivery of chemotherapeutic drugs, immune antigens, and cancer vaccine adjuvants. EVs-based therapy may represent the next-generation tool for targeted drug delivery for the cure of a variety of diseases lacking effective drug treatment.

Citing Articles

Ex.50.T aptamer impairs tumor-stroma cross-talk in breast cancer by targeting gremlin-1.

Quintavalle C, Ingenito F, Roscigno G, Pattanayak B, Esposito C, Affinito A Cell Death Discov. 2025; 11(1):94.

PMID: 40069570 PMC: 11897156. DOI: 10.1038/s41420-025-02363-6.

A game of hide-and-seek: how extracellular vesicles evade the immune system.

Ghoshal B, Jhunjhunwala S Drug Deliv Transl Res. 2025; .

PMID: 39843837 DOI: 10.1007/s13346-025-01789-w.

Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy.

Mengistu B, Tsegaw T, Demessie Y, Getnet K, Bitew A, Kinde M Cancer Cell Int. 2024; 24(1):406.

PMID: 39695669 PMC: 11657890. DOI: 10.1186/s12935-024-03558-0.

Extracellular Vesicles in Breast Cancer: From Intercellular Communication to Therapeutic Opportunities.

Muttiah B, Ng S, Lokanathan Y, Ng M, Law J Pharmaceutics. 2024; 16(5).

PMID: 38794316 PMC: 11125876. DOI: 10.3390/pharmaceutics16050654.

References

Lim A, Rathmell W, Rathmell J . The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 2020; 9. PMC: 7200151. DOI: 10.7554/eLife.55185. View

Li X, Wang S, Mu W, Barry J, Han A, Carpenter R . Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway. J Exp Clin Cancer Res. 2022; 41(1):41. PMC: 8793215. DOI: 10.1186/s13046-022-02244-1. View

Katoh M . Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med. 2013; 32(4):763-7. PMC: 3812243. DOI: 10.3892/ijmm.2013.1444. View

Chen H, Huang C, Wu Y, Sun N, Deng C . Exosome Metabolic Patterns on Aptamer-Coupled Polymorphic Carbon for Precise Detection of Early Gastric Cancer. ACS Nano. 2022; 16(8):12952-12963. DOI: 10.1021/acsnano.2c05355. View

Behera J, Kumar A, Voor M, Tyagi N . Exosomal lncRNA-H19 promotes osteogenesis and angiogenesis through mediating Angpt1/Tie2-NO signaling in CBS-heterozygous mice. Theranostics. 2021; 11(16):7715-7734. PMC: 8315071. DOI: 10.7150/thno.58410. View

Olejarz W, Dominiak A, Zolnierzak A, Kubiak-Tomaszewska G, Lorenc T . Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. J Immunol Res. 2020; 2020:6272498. PMC: 7261328. DOI: 10.1155/2020/6272498. View

Wei K, Zhang H, Yang S, Cui Y, Zhang B, Liu J . Chemo-drugs in cell microparticles reset antitumor activity of macrophages by activating lysosomal P450 and nuclear hnRNPA2B1. Signal Transduct Target Ther. 2023; 8(1):22. PMC: 9852455. DOI: 10.1038/s41392-022-01212-7. View

Yu Z, Tang H, Chen S, Xie Y, Shi L, Xia S . Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy. Drug Resist Updat. 2023; 67:100915. DOI: 10.1016/j.drup.2022.100915. View

Zhang N, Shu G, Qiao E, Xu X, Shen L, Lu C . DNA-Functionalized Liposomes Fusion for NIR-II/MRI Guided Pretargeted Ferroptosis Therapy of Metastatic Breast Cancer. ACS Appl Mater Interfaces. 2022; 14(18):20603-20615. DOI: 10.1021/acsami.2c01105. View

10.

Psaraki A, Ntari L, Karakostas C, Korrou-Karava D, Roubelakis M . Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases. Hepatology. 2021; 75(6):1590-1603. DOI: 10.1002/hep.32129. View

11.

Betzer O, Barnoy E, Sadan T, Elbaz I, Braverman C, Liu Z . Advances in imaging strategies for in vivo tracking of exosomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 12(2):e1594. DOI: 10.1002/wnan.1594. View

12.

Li Z, Li Y, Li Y, Ren K, Li X, Han X . Long non-coding RNA H19 promotes the proliferation and invasion of breast cancer through upregulating DNMT1 expression by sponging miR-152. J Biochem Mol Toxicol. 2017; 31(9). DOI: 10.1002/jbt.21933. View

13.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

14.

Friedman G, Johnston J, Bag A, Bernstock J, Li R, Aban I . Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med. 2021; 384(17):1613-1622. PMC: 8284840. DOI: 10.1056/NEJMoa2024947. View

15.

Goler-Baron V, Sladkevich I, Assaraf Y . Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 2012; 83(10):1340-8. DOI: 10.1016/j.bcp.2012.01.033. View

16.

Xu X, Lai Y, Hua Z . Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2018; 39(1). PMC: 6340950. DOI: 10.1042/BSR20180992. View

17.

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

18.

Debbi L, Guo S, Safina D, Levenberg S . Boosting extracellular vesicle secretion. Biotechnol Adv. 2022; 59:107983. PMC: 9420194. DOI: 10.1016/j.biotechadv.2022.107983. View

19.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

20.

Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J . Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett. 2022; 548:215823. DOI: 10.1016/j.canlet.2022.215823. View